Deleted Journal,
Journal Year:
2024,
Volume and Issue:
1(1), P. 100009 - 100009
Published: May 11, 2024
Heterogeneity
within
the
solid
tumor
microenvironment
contributes
to
a
poor
prognosis
and
limited
therapeutic
responses.
Companion
diagnostics
(CDx),
clinical
technique
that
gives
doctors
vital
biomarker
information
enhance
patient
outcomes
through
matching
specific
treatments
patients,
is
becoming
more
important.
However,
most
current
US
Food
Drug
Administration
(FDA)-approved
CDx
tests
have
difficulty
dynamically
reflecting
variations
in
biomarkers
because
they
are
used
vitro
ex
vivo.
Consequently,
new
medical
imaging-based
been
widely
detect
interpatient
intrapatient
heterogeneity
assess
intratumoral
distribution
of
variables.
They
provide
stratification
for
targeted
therapies
differentiation
populations
benefit
from
alternative
treatments.
This
review
provides
an
overview
recent
advances
tumors
summarizes
various
utilized
CDx.
We
believe
this
offers
additional
details
directions
promoting
development.
Journal of Materials Chemistry B,
Journal Year:
2024,
Volume and Issue:
12(21), P. 5157 - 5161
Published: Jan. 1, 2024
The
ability
to
detect
and
visualize
cellular
events
associated
biological
analytes
is
essential
for
the
understanding
of
their
physiological
pathological
functions.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(34), P. 23599 - 23614
Published: Aug. 14, 2024
Atherosclerosis
(AS)
is
a
chronic
inflammatory
disorder
characterized
by
arterial
intimal
lipid
plaques.
Small
interfering
ribonucleic
acid
(siRNA)-based
therapies,
with
their
ability
to
suppress
specific
genes
high
targeting
precision
and
minimal
side
effects,
have
shown
great
potential
for
AS
treatment.
However,
targets
of
siRNA
therapies
based
on
macrophages
treatment
are
still
limited.
Olfactory
receptor
2
(Olfr2),
target
plaque
formation,
was
discovered
recently.
Herein,
anti-Olfr2
(si-Olfr2)
designed,
the
theranostic
platform
encapsulating
si-Olfr2
within
atherosclerotic
lesions
also
developed,
aim
downregulating
Olfr2,
as
well
diagnosing
through
photoacoustic
imaging
(PAI)
in
second
near-infrared
(NIR-II)
window
resolution.
By
utilization
reactive
oxygen
species
(ROS)-responsive
nanocarrier
system,
expression
Olfr2
plaques
effectively
downregulated,
leading
inhibition
NLR
family
pyrin
domain
containing
3
(NLRP3)
inflammasome
activation
interleukin-1
β
(IL-1β)
secretion,
thereby
reducing
formation
As
manifested
decreased
expression,
exhibited
significantly
alleviated
response
that
led
reduced
deposition,
macrophage
apoptosis,
noticeable
decrease
necrotic
areas.
This
study
provides
proof
concept
evaluating
nanoplatform
specifically
deliver
lesional
diagnosis
Deleted Journal,
Journal Year:
2024,
Volume and Issue:
1(1), P. 100009 - 100009
Published: May 11, 2024
Heterogeneity
within
the
solid
tumor
microenvironment
contributes
to
a
poor
prognosis
and
limited
therapeutic
responses.
Companion
diagnostics
(CDx),
clinical
technique
that
gives
doctors
vital
biomarker
information
enhance
patient
outcomes
through
matching
specific
treatments
patients,
is
becoming
more
important.
However,
most
current
US
Food
Drug
Administration
(FDA)-approved
CDx
tests
have
difficulty
dynamically
reflecting
variations
in
biomarkers
because
they
are
used
vitro
ex
vivo.
Consequently,
new
medical
imaging-based
been
widely
detect
interpatient
intrapatient
heterogeneity
assess
intratumoral
distribution
of
variables.
They
provide
stratification
for
targeted
therapies
differentiation
populations
benefit
from
alternative
treatments.
This
review
provides
an
overview
recent
advances
tumors
summarizes
various
utilized
CDx.
We
believe
this
offers
additional
details
directions
promoting
development.
